ALK and lung carcinoma: We constructed a CCCN and CFN from measurements of phosphorylation, acetylation, and ubiquitination in 10 different lung cancer cell lines with driver mutations in EGFR, ALK, ERBB2/HER2, ROS1, and DDR2, treated with four different TKIs.